Comparative Pharmacology
Head-to-head clinical analysis: FEMSTAT versus FULVICIN P G 330.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FEMSTAT versus FULVICIN P G 330.
FEMSTAT vs FULVICIN P/G 330
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FEMSTAT (butoconazole) is an imidazole antifungal agent that inhibits fungal cytochrome P450 14α-demethylase, thereby blocking the conversion of lanosterol to ergosterol, a key component of the fungal cell membrane. This disrupts membrane integrity and function, leading to fungal cell death.
Fulvicin P/G 330 contains griseofulvin, which inhibits fungal cell mitosis by disrupting the microtubule function, binding to tubulin and preventing assembly of spindle fibers during metaphase.
Butoconazole nitrate 2% vaginal cream: one applicatorful (approximately 5 g) intravaginally at bedtime for 3 days. Alternatively, butoconazole nitrate 2% single-dose vaginal cream: one applicatorful (approximately 5 g) intravaginally as a single dose.
330 mg orally once daily with fatty meal to enhance absorption.
None Documented
None Documented
Terminal half-life: 6-9 hours; clinical context: supports twice-daily dosing for consistent therapeutic levels.
Terminal half-life approximately 9-22 hours in adults, with a mean of ~13 hours. Clinical context: steady-state achieved in 2-3 days; may guide dosing interval.
Primarily hepatic metabolism; <10% excreted unchanged in urine. Fecal excretion accounts for approximately 30% of metabolites.
Primarily hepatic metabolism; <1% excreted unchanged in urine. Biliary/fecal excretion of metabolites: ~36% in feces, ~13% in urine.
Category C
Category C
Antifungal
Antifungal